“The European Medicines Agency (EMEA) says the authorization that was granted two years ago to Sanofi-Aventis to market its anti-obesity drug Acomplia (rimonabant) in the Eropean Union (EU) should be suspended because the drug's advantages don't outweigh the potential disadvantages which include a doubling of the risk of developing psychiatric disorders such as depression when compared with placebo.”
http://www.medicalnewstoday.com/articles/126658.php
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment